Growth response to growth hormone treatment in patients with SHOX deficiency can be predicted by the Cologne prediction model.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The aim was to investigate whether this model also applies to patients with SHOX deficiency.

Why It Was Studied

Prediction of growth response continues to be a challenge.

A comparatively accurate method is the Cologne prediction model developed in children with GH deficiency.

Who Took Part

The abstract describes 48 patients taking part.

PubMed tags the participants as both men and women.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Topics PubMed links to this paper include Body Height, Growth Disorders, Human Growth Hormone, Models, Statistical, Mutation, Predictive Value of Tests and Short Stature Homeobox Protein.

Author keywords: growth prediction, height velocity and short stature homeobox-containing gene (SHOX).

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 48 patients.

The abstract goes on to report its results in about 1 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.